相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia
Yiqian Wang et al.
CANCER GENE THERAPY (2020)
CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy
Ashraf Mousavi
IMMUNOLOGY LETTERS (2020)
Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy
Michael-Joseph Gorbet et al.
PHARMACOLOGY & THERAPEUTICS (2020)
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Ina Nepstad et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia
Ramprasad Ramakrishnan et al.
CELL REPORTS (2020)
Bone marrow niches in haematological malignancies
Simon Mendez-Ferrer et al.
NATURE REVIEWS CANCER (2020)
A rare subgroup of leukemia stem cells harbors relapse-inducing potential in acute lymphoblastic leukemia
Daniela Senft et al.
EXPERIMENTAL HEMATOLOGY (2019)
Radionuclide- Labeled Peptides for Imaging and Treatment of CXCR4-Overexpressing Malignant Tumors
Nan Liu et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation
Sabine Maurer et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation
Zhihong Zeng et al.
ACTA HAEMATOLOGICA (2019)
Normal and leukemic stem cell niche interactions
Il-Hoan Oh et al.
CURRENT OPINION IN HEMATOLOGY (2019)
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia
Michael Steurer et al.
HAEMATOLOGICA (2019)
BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
Sujan Piya et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Context-Dependent Signaling of CXC Chemokine Receptor 4 and Atypical Chemokine Receptor 3
Joyce Heuninck et al.
MOLECULAR PHARMACOLOGY (2019)
Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia
Tingyong Cao et al.
MEDICINE (2019)
Clinical and Therapeutic Implications of Cancer Stem Cells
Michael F. Clarke
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A novel dimeric CXCR4 antagonist synergizes with chemotherapy in acute myeloid leukaemia by mobilizing leukaemic cells from their associated bone marrow niches
Yazi Huang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
The cell of origin and the leukemia stem cell in acute myeloid leukemia
Martin Chopra et al.
GENES CHROMOSOMES & CANCER (2019)
Modulators of CXCR4 and CXCR7/ACKR3 Function
Ilze Adlere et al.
MOLECULAR PHARMACOLOGY (2019)
Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3
Vladimir Bobkov et al.
MOLECULAR PHARMACOLOGY (2019)
Prognostic significance of CXCR4 expression in acute myeloid leukemia
Wen Du et al.
CANCER MEDICINE (2019)
CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma
Geoffrey L. Uy et al.
BLOOD (2019)
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS
Eric Huselton et al.
BLOOD (2019)
SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy
Kuo Jiang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
[68Ga]Ga/[177Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4
Joseph Lau et al.
MOLECULAR PHARMACEUTICS (2019)
The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia
Tingyong Cao et al.
SCIENTIFIC REPORTS (2019)
C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4
Kentaro Suzuki et al.
SCIENTIFIC REPORTS (2019)
Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability
Fotios V. Michelis et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Targeting PI3K Signaling in Acute Lymphoblastic Leukemia
Vanessa Edna Sanchez et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
Maria Jose Costa et al.
SCIENTIFIC REPORTS (2019)
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
Nicholas J. Short et al.
LEUKEMIA & LYMPHOMA (2018)
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
David Martinez-Cuadron et al.
ANNALS OF HEMATOLOGY (2018)
The interplay of leukemia cells and the bone marrow microenvironment
Delfim Duarte et al.
BLOOD (2018)
Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies
Amnon Peled et al.
CYTOKINE (2018)
The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential
Dian Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
Gail J. Roboz et al.
HAEMATOLOGICA (2018)
A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia
Mael Heiblig et al.
LEUKEMIA RESEARCH (2018)
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Andrew M. Kidger et al.
PHARMACOLOGY & THERAPEUTICS (2018)
A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics
Maria Jose Costa et al.
PLOS ONE (2018)
Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin
Raquel Diaz et al.
SMALL (2018)
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
Stefan Habringer et al.
THERANOSTICS (2018)
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
Gail J. Roboz et al.
HAEMATOLOGICA (2018)
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Feifei Liu et al.
ACTA PHARMACEUTICA SINICA B (2018)
Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions
Christian M. Schurch
FRONTIERS IN ONCOLOGY (2018)
CXCR4-directed theranostics in oncology and inflammation
Malte Kircher et al.
ANNALS OF NUCLEAR MEDICINE (2018)
New Approaches to the Management of Adult Acute Lymphoblastic Leukemia
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q-AML
Belen Lopez-Millan et al.
ONCOIMMUNOLOGY (2018)
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Prajwal Boddu et al.
FRONTIERS IN ONCOLOGY (2018)
Biased antagonism of CXCR4 avoids antagonist tolerance
Ben Hitchinson et al.
SCIENCE SIGNALING (2018)
Peripheral Blood Stem Cell Mobilization: a Look Ahead
Louis M. Pelus et al.
CURRENT STEM CELL REPORTS (2018)
Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia
Tibor J. Kovacsovics et al.
BLOOD ADVANCES (2018)
The hematopoietic stem-cell niche in health and leukemia
Abel Sanchez-Aguilera et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
New agents in HSC mobilization
Meanie Domingues et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
M. Abraham et al.
LEUKEMIA (2017)
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
H. Ludwig et al.
LEUKEMIA (2017)
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03)
Todd M. Cooper et al.
PEDIATRIC BLOOD & CANCER (2017)
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
G. L. Uy et al.
BLOOD CANCER JOURNAL (2017)
Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET
Ido D. Weiss et al.
ONCOTARGET (2017)
[177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
Margret Schottelius et al.
THERANOSTICS (2017)
Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
Byung-Sik Cho et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2017)
Pathophysiology of GvHD and Other HSCT-Related Major Complications
Sakhila Ghimire et al.
FRONTIERS IN IMMUNOLOGY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers
Michal Abraham et al.
CLINICAL CANCER RESEARCH (2017)
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
Mark A. Schroeder et al.
BLOOD (2017)
Biology and relevance of human acute myeloid leukemia stem cells
Daniel Thomas et al.
BLOOD (2017)
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
Ken Herrmann et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
Manoj K. Kashyap et al.
ONCOTARGET (2016)
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting
Francesca Chiarini et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
A prognostic model for survival after salvage treatment with FLAG-Ida plus /- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
Juan M. Bergua et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma
Federica Barbieri et al.
EXPERT OPINION ON DRUG DISCOVERY (2016)
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia
Peter Herhaus et al.
HAEMATOLOGICA (2016)
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
Michael M. B. Green et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Adult Acute Lymphoblastic Leukemia
Shilpa Paul et al.
MAYO CLINIC PROCEEDINGS (2016)
CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients
Diane Goltz et al.
ONCOTARGET (2016)
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia
Peter Herhaus et al.
HAEMATOLOGICA (2016)
Cell Adhesion Molecules in Normal and Malignant Hematopoiesis: from Bench to Bedside
Jean-Pierre Levesque et al.
CURRENT STEM CELL REPORTS (2016)
VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia
Mi Hyun Bae et al.
ANNALS OF HEMATOLOGY (2015)
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy
Byung-Sik Cho et al.
BLOOD (2015)
How I treat refractory and early relapsed acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2015)
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation
M. Konopleva et al.
BONE MARROW TRANSPLANTATION (2015)
CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance
Lauren A. Pitt et al.
CANCER CELL (2015)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi et al.
LANCET ONCOLOGY (2015)
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia
Geoffrey L. Uy et al.
LEUKEMIA RESEARCH (2015)
A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment
A-Reum Han et al.
ONCOLOGY REPORTS (2015)
Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine
Ling Qin et al.
SCIENCE (2015)
POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL
Edward Allan R. Sison et al.
ONCOTARGET (2015)
Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis
Xiaojin Li et al.
SCIENTIFIC REPORTS (2015)
Prospective Study of Ga-68-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients
Zhe Wang et al.
THERANOSTICS (2015)
Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging
Hans Juergen Wester et al.
THERANOSTICS (2015)
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation
Aldo M. Roccaro et al.
CELL REPORTS (2015)
Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models
Sheng-Bin Peng et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A CXCR4-Targeted Site-Specific Antibody-Drug Conjugate
Sumith A. Kularatne et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia
Ashok Srinivasan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia
Lieke C. J. van den Berk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia
Francesco Mannelli et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2014)
High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia
Sun-Young Ko et al.
LEUKEMIA RESEARCH (2014)
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition
Edward Allan R. Sison et al.
ONCOTARGET (2014)
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy
Aldo M. Roccaro et al.
CELL REPORTS (2014)
CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands
C. Castaldo et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.
Michael Andreeff et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism
Edward Allan R. Sison et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies
Michelle R. Kuhne et al.
CLINICAL CANCER RESEARCH (2013)
Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12
A. Vater et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Urszula M. Domanska et al.
EUROPEAN JOURNAL OF CANCER (2013)
Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice
Robert Welschinger et al.
EXPERIMENTAL HEMATOLOGY (2013)
Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study
Marc Maynadie et al.
HAEMATOLOGICA (2013)
Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML
Edward Allan R. Sison et al.
MOLECULAR CANCER RESEARCH (2013)
CXCL12 in early mesenchymal progenitors is. required for haematopoietic stem-cell maintenance
Adam Greenbaum et al.
NATURE (2013)
Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches
Lei Ding et al.
NATURE (2013)
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies
Krystin Krauel et al.
BLOOD (2012)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
Is the post-transplantation treatment with AMD beneficial?
Yi Jiang et al.
BLOOD CELLS MOLECULES AND DISEASES (2012)
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial
Jonathan I. Sive et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4
M. P. Rettig et al.
LEUKEMIA (2012)
Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy
Yordanos Tesfai et al.
LEUKEMIA RESEARCH (2012)
Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH)
Manali V. Joglekar et al.
THROMBOSIS AND HAEMOSTASIS (2012)
The Prognostic Value of CXCR4 in Acute Myeloid Leukemia
Jeong Yeal Ahn et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
Phosphorylated CXCR4 Is Associated With Poor Survival in Adults With B-Acute Lymphoblastic Leukemia
Sergej Konoplev et al.
CANCER (2011)
Modern Therapy of Acute Lymphoblastic Leukemia
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
R. Parameswaran et al.
LEUKEMIA (2011)
Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles
Sergey G. Tarasov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo
M. Yu et al.
BLOOD CANCER JOURNAL (2011)
HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor
Yu Feng et al.
JOURNAL OF IMMUNOLOGY (2011)
Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands
Narayanam V. Rao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2010)
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2010)
Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells
Iskra Pusic et al.
CURRENT OPINION IN HEMATOLOGY (2010)
Activity of the Aurora Kinase Inhibitor VX-680 against Bcr/Abl-Positive Acute Lymphoblastic Leukemias
Fei Fei et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation Model
Yubin Kang et al.
PLOS ONE (2010)
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers
Erik De Clercq
PHARMACOLOGY & THERAPEUTICS (2010)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists
Beili Wu et al.
SCIENCE (2010)
The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)
Erik De Clercq
BIOCHEMICAL PHARMACOLOGY (2009)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng et al.
BLOOD (2009)
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
Bruno Nervi et al.
BLOOD (2009)
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
John F. DiPersio et al.
BLOOD (2009)
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma
John F. DiPersio et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia
Emmanuelle Tavernier-Tardy et al.
LEUKEMIA RESEARCH (2009)
Reassessment of CXCR4 Chemokine Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-2
Thomas Fischer et al.
PLOS ONE (2008)
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype
Sergej Konoplev et al.
CANCER (2007)
CXCR4 is a prognostic marker in acute myelogenous leukemia
Anke C. Spoo et al.
BLOOD (2007)
Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches
Tatsuki Sugiyama et al.
IMMUNITY (2006)
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia
MR Ricciardi et al.
LEUKEMIA (2005)
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
PL Greenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia
EJC Rombouts et al.
BLOOD (2004)
Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent
H Tamamura et al.
FEBS LETTERS (2004)
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
B Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Is high expression of the chemokine receptor CXCR-4 of predictive value for early relapse in childhood acute lymphoblastic leukaemia?
P Schneider et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia
R Crazzolara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
R Mohle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
